PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Secondary Databased Post-marketing Surveillance Study of BNT162b2
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10890000
- Registration Number
- NCT06743334
- Locations
- 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
Not yet recruiting
- Conditions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT06735742
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
Not yet recruiting
- Conditions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT06733337
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 252
- Registration Number
- NCT06717425
A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06712082
A Study to Learn if the Study Medicine Called Itraconazole Changes How the Body Processes the Other Study Medicine Called PF-07258669 In Older Adults
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT06706869
A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT06705569
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene
Phase 1
Not yet recruiting
- Conditions
- Interventions
- Drug: PF-07985045Combination Product: GemcitabineCombination Product: CetuximabCombination Product: FluorouracilCombination Product: PembrolizumabCombination Product: PF-07284892Combination Product: Nab-paclitaxelCombination Product: OxaliplatinCombination Product: SasanlimabCombination Product: pemetrexedCombination Product: LeucovorinCombination Product: CisplatinCombination Product: BevacizumabCombination Product: PaclitaxelCombination Product: Carboplatin
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT06704724
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT06703606
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22692
- Registration Number
- NCT06703190
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
© Copyright 2024. All Rights Reserved by MedPath